Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154590 | 0.91 | EPHX2 (0.47) | HDAC8EPHX2MASP2 | |
| SCHEMBL3144705 | 0.86 | MASP2 (0.49) | HDAC8MASP2HDAC1 | |
| SCHEMBL3139300 | 0.86 | MASP2 (0.47) | EPHX2MASP2 | |
| SCHEMBL3144724 | 0.83 | MASP2 (0.46) | HDAC8EPHX2MASP2 | |
| SCHEMBL3153403 | 0.83 | MASP2 (0.45) | EPHX2MASP2HDAC1 | |
| Hydrochloric Acid SCHEMBL1432716 | 0.82 | MASP2 (0.45) | EPHX2MASP2HDAC1 | |
| Hydrochloric Acid SCHEMBL1432721 | 0.82 | MASP2 (0.45) | EPHX2MASP2HDAC1 | |
| SCHEMBL3140035 | 0.80 | MASP2 (0.45) | MASP2HDAC1 | |
| SCHEMBL4313109 | 0.79 | EPHX2 (0.48) | EPHX2MASP2 | |
| SCHEMBL1903414 | 0.78 | EPHX2 (0.47) | HDAC8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | HDAC8 4009/4885EPHX2 3143/4885MASP2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.